BioSpace News Archive

Axsome Therapeutics, Inc. announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees.

STERIS plc announced that the U.S. Food and Drug Administration has issued another Emergency Use Authorization for respirator decontamination.

Centene Corporation announced that it has donated $500,000 to the National Domestic Violence Hotline, which aims to support and advocate for those affected by relationship abuse.

Qualigen Therapeutics, Inc., has completed its previously announced merger transaction with Qualigen, Inc., a company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the worldwide sales of its flagship FastPack® rapid diagnostic platform.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced its financial results for the first quarter, ended March 31, 2020.

OSE Immunotherapeutics, announced the signature of a €7 million non-dilutive loan agreement, with a pool of French banks, providing the company with further financing to advance its clinical and preclinical development programs.

Selvita, one of the largest preclinical contract research organizations in Europe, reported its first quarter 2020 financial results and provided a corporate update.

Medivir AB announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company.

Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities and Leica Biosystems, a global leader in workflow solutions and automation, are proud to announce the European launch of the CE-IVD marked RNAscope™ In Situ Hybridization Detection Kit for automation on the BOND-III platform.

Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience